| scholarly article | Q13442814 |
| P2093 | author name string | Burke SJ | |
| Ghim SJ | |||
| Goldman DM | |||
| Hewitt LA | |||
| Jenson AB | |||
| Koenig S | |||
| Palmer-Hill FJ | |||
| Suzich JA | |||
| White WI | |||
| Wilson SD | |||
| Woods RM | |||
| P2860 | cites work | Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. | Q39875296 |
| Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies | Q41172103 | ||
| Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | Q41203441 | ||
| Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. | Q42625647 | ||
| Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation | Q45771837 | ||
| The structure of viruses of the papilloma-polyoma type 3. Structure of rabbit papilloma virus, with an appendix on the topography of contrast in negative-staining for electron-microscopy | Q45826136 | ||
| Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. | Q52277987 | ||
| A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera | Q73685389 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Site-directed mutagenesis by overlap extension using the polymerase chain reaction | Q27860503 | ||
| Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 | ||
| Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies | Q33785841 | ||
| Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines | Q33785870 | ||
| In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. | Q34069054 | ||
| Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition | Q35860748 | ||
| Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly | Q35880936 | ||
| Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope | Q35890718 | ||
| Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles | Q36654802 | ||
| Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. | Q39577044 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4882-4889 | |
| P577 | publication date | 1999-06-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Characterization of a major neutralizing epitope on human papillomavirus type 16 L1 | |
| P478 | volume | 73 |
| Q41606985 | A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment |
| Q40238745 | A deletion and point mutation study of the human papillomavirus type 16 major capsid gene |
| Q36673310 | A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response |
| Q36448778 | A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5 |
| Q45362152 | A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: a possible indicator of immunogenicity |
| Q43096878 | Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity |
| Q47143249 | Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36. |
| Q43957819 | Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles |
| Q44046271 | Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands |
| Q36088309 | Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles |
| Q24796150 | Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope |
| Q35079915 | Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. |
| Q35155333 | Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 |
| Q36333638 | Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection |
| Q33950282 | Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. |
| Q34477334 | Development of a highly thermostable, adjuvanted human papillomavirus vaccine |
| Q44105400 | Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques |
| Q33652425 | Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions |
| Q34074835 | Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. |
| Q33743226 | Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18 |
| Q35925828 | Evidences of Changes in Surface Electrostatic Charge Distribution during Stabilization of HPV16 Virus-Like Particles |
| Q42785059 | Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. |
| Q64377560 | HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice |
| Q40639970 | Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines |
| Q47136931 | High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16. |
| Q35235035 | How will HPV vaccines affect cervical cancer? |
| Q33908917 | Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers |
| Q39793237 | Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses |
| Q36541188 | Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1 |
| Q33469751 | Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications |
| Q39683911 | Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses |
| Q42038224 | Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. |
| Q90836400 | Immunogenicity of Protein Pharmaceuticals |
| Q73414358 | Immunological analyses of human papillomavirus capsids |
| Q43616965 | Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope |
| Q34860943 | Interactions between papillomavirus L1 and L2 capsid proteins |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q37808256 | Monitoring of human papillomavirus vaccination. |
| Q35861286 | Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype |
| Q35947703 | Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition |
| Q26801497 | Papillomavirus Infectious Pathways: A Comparison of Systems |
| Q33847557 | Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses |
| Q33575647 | Potential anti-HPV and related cancer agents from marine resources: an overview |
| Q33974260 | Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes |
| Q98163575 | Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women |
| Q57131032 | Production and characterization of a novel HPV anti-L2 monoclonal antibody panel |
| Q36555514 | Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells |
| Q34315981 | Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells |
| Q33879132 | Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation |
| Q34347179 | Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein |
| Q35866498 | Replication and assembly of human papillomaviruses |
| Q34579346 | Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay |
| Q27625236 | Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 |
| Q37373696 | Structure, attachment and entry of polyoma- and papillomaviruses |
| Q91688100 | Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity |
| Q35559857 | The Clinical Significance of HPV |
| Q36281141 | The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy |
| Q34259805 | The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles |
| Q33970900 | The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network |
| Q57560056 | Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector |
| Q36793117 | Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination |
| Q37185155 | Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China |
| Q37480444 | Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus |
Search more.